A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 264 participants.

Also called NCT06933472

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 264 participants (planned count) (from the registry)
Sponsor
  • Fortrea Registry lists this organization as a collaborator
Registry
  • NCT NCT06933472
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06933472. Randomized; quadruple masking; primary purpose treatment. Start 2025-06-13 (actual); primary completion 2026-06-20 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China
Acronym
RESPOND-2
Condition
Hyperphosphatemia
Condition
Chronic Kidney Disease, Receiving Dialysis
Condition
ESRD (End-Stage Renal Disease)
Condition
Dialysis
Intervention (Drug)
AP301
Intervention (Drug)
AP301 Low Dose
Lead sponsor
Alebund Pharmaceuticals (class: industry)
Collaborator
Fortrea (class: industry)

Record details

Record id
cardio:ct-nct06933472
Content hash
3c03c48b9487d2f00bd4ce124aea53a6f6b997bf2edff0ca39cb189dc63a5012